参考文献/References:
［1］ HAVERKAMP F，WUENSCH S，FUCHS M，STEWART WC.Intraocular pressuer，safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments［J］.Eur J Ophthalmol，2004，14（5）：407-415.
［2］ GONZLEZ-MENDIOLA MR，BALDA AG，DELGADO MC，MON-TAO PP，DE OLANO DG，SNCHEZ-CANO M.Contact allergy from tobramycin eyedrops［J］.Allergy，2005，60（4）：527-528.
［3］ MANNI G，CENTOFANTI M，SACCHETTI M，ODDONE F，BONINI S，PARRAVANO M，et al.Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy［J］.J Glaucoma，2004，13（2）：163-167.
［4］ BAUDOUIN C，LIANG H，HAMARD P，RIANCHO L，CREUZOT-GARCHER C，WARNET JM，et al.The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways［J］.Ophthalmology，2008，115（1）：109-115.
［5］ BAUDOUIN C，HAMARD P，LIANG H，CREUZOT-GARCHER C，BENSOUSSAN L，BRIGOLE F.Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term［J］.Ophthalmology，2004，111（12）：2186-2192.
［6］ BAUDOUIN C，LABB A，LIANG H，PAULY A，BRIGNOLE-BAUDOUIN F.Preservatives in eyedrops：the good，the bad and the ugly［J］.Prog Retin Eye Res，2010，29（4）：312-324.
［7］ UTER W，LESSMANN H，GEIER J，SCHNUCH A.Is the irritant benzalkonium chloride a contact allergen?A contribution to the ongoing debate from a clinical perspective［J］.Contact Derm，2008，58（6）：359-363.
［8］ VALENTE C，LESTER M.Impact of glaucoma medication on occular tissue［J］.Expert Rev Ophthalmol，2010，5（3）：405-412.
［9］ KNOP E，KONP N.Influence of the eye-associated lymphoid tissue（EALT） on inflammatory ocular surface disease［J］.Ocul Surf，2005，3（4 Suppl）：180-186.
［10］ KNOP E，KONP N.Ultrastructural anatomy of CALT follicles in the rabbit reveals characteristics of M-cells，germinal centres and high endothelial venules［J］.J Anat，2005，207（4）：409-426.
［11］ LIANG H，BAUDOUIN C，LABBE A，RIANCHO L，BRIGNOLE-BAUDOUIN F.Conjunctiva-associated lymphoid tissue（CALT） reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study［J］.PLoS One，2012，7（3）：e33913.
［12］ ROSENWASSER GOD.Complications of topical ocular anesthetics［J］.Int Opthalmol Clin，1989，29（2）：153-158.
［13］ VARGA JH，RUBINFELD RS，WOLF TC.Topical anesthetic abuse ring keratitis：report of four cases［J］.Cornea，1997，16（4）：424-429.
［14］ YENIAD B，CANTURK S，ESIN OZDEMIR F，ALPARSLAN N，AKARCAY K.Toxic keratopathy due to abuse of topical anesthetic drugs［J］.Cutan Ocul Toxicol，2010，29（2）：105-109.
［15］ CHEN HT，CHEN KH，HSU WM.Toxic keratopathy associated with abuse of low-dose anesthetic：a case report［J］.Cornea，2004，23（5）：527-529.
［16］ BORCH JE，ELMQUIST JS，BINDSLEV-JENSEN C，ANDERSEN KE.Phenylephrine and acute periorbital dermatitis［J］.Contact Derm，2005，53（5）：298-299.
［17］ RAISON-PEYRON N，THANH A DU，DEMONLY P，GUILLOT B.Long-lasting allergic contact blepharoconjunctivitis to phenylephrine eyedrops［J］.Allergy，2009，64（4）：657-658.
［18］ FREW A.Selected side effects：non-steroidal anti-inflammatory drugs and asthma［J］.Prescr J，1994，34（4）：2.
［19］ LYALL D，MCQUEEN M，RAMAESH K,WEIR C.A sting in the tale：cross reaction hypersensitivity to hyaluronidase［J］.Eye，2012，26（11）：1490.
［20］ AHLUWALIA HS，LUKARIS A，LANE CM.Delayed allergic reaction to hyaluronidase：a rare sequel to cataract suigery［J］.Eye，2003，17（2）：263-266.
［21］ MENCUCCI R，PELLEGRINI-GIAMPIETRO DE，PALADINI I，FAVUZZA E，MENCHINI U，SCARTABELLI T.Azithromycin：assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures［J］.Clin Ophthalmol，2013，7（7）：965-971.
［22］ WASSERMAN BN，LISS KP.Recurrent corneal ulceration as late complication of toxic keratitis［J］.Br J Ophthalmol，2002，86（2）：245-246.
［23］ BRUCE RA，MCGOLDRICK KE，OPPENHEIMER P.Anesthesia for ophthalmology［M］.Birmingham：Aesculapius，1982：29.
［24］ DASS BA，SOONG HK，LEE B.Effects of proparacaine on actin and vinculin in corneal epithelium（abstract）［J］.Invest Ophthalmol Vis Sci，1988，29（9）：53.
［25］ RISO JM，MILLAR LC.Ultratructural alterations in the endothelium in a patient with topical anesthetic abuse keratopathy［J］.Ophthalmology，1992，99（4）：628-633.
［26］ MARTONE G，FREZZOTTI P，TOSI GM，TRAVERSI C，MITTICA V，MALANDRINI A，et al.An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology［J］.Am J Ophthalmol，2009，147（4）：725-735.
［27］ HERERAS JM，PASTOR JC，CALONGE M，ASENSIO VM.Ocular surface alteration afer long-term treatment with an antigalucomatous drug［J］.Ophthalmology，1992，99（7）：1082-1088.
［28］ ARTHUR BW，HAY GJ，WASAN SM，WILLIS WE.Ultrastuctural effects of topical timolol on the rabbit corna［J］.Arch Ophthalmol，1983，101（10）：1607-1610.
［29］ NENCIU A，STEFAN C，ARDELEAN C.Strucrutal and immunohistochemical changes of conjunctiva induced by topical glaucoma medication［J］.Oftalmologia，2004，48（1）：35-42.
［30］ DOGˇAN AS，ORHAN M，SYLEMEZOG′LU F，IRKE M，BOZKURT B.Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients［J］.Clin Exp Ophthalmol，2004，32（1）：62-66.
［31］ CUNNINGHAM KE，TURNER JR.Myosin light chain kinase：pulling the strings of epithelial tight junction function［J］.Ann N Y Acad Sci，2012，1258（12）：34-42.
［32］ CENAC N，GARCIA-VILLAR R，FERRIER L，LARAUCHE M，VERGNOLLE N，BUNNETT NW，et al.Proteinase-activated receptor-2-induced colonic inflammation in mice：possible involvement of afferent neurons，nitric oxide，and parcellular permeability［J］.J Immunol，2003，170（8）：4276-4300.
［33］ SHEN L.Tight junctions on the move：molecular mechanisms for epithelial barrier regulation［J］.Ann N Y Acad Sci，2012,1258（12）：9-18.
［34］ GUO Y，SATPATHY M，WILSON G，SRINIVAS S.Benzalkonium chloride induces dephosphorylation of myosin light chain in cultured corneal epithelial cells［J］.Invest Ophthalmol Vis Sci，2007，48（5）：2001-2008.
［35］ GASSLER N，ROHR C，SCHNEIDER A，KARTENBECK J，BACH A，OBERMüLLER N，et al.Inflammatory bowel disease is associated with changes of enterocytic junctions［J］.Am J Physiol Gastrointest Liver Physiol，2001，281（1）：G216-228.
［36］ ISHIBASHI T，YOKOI N，KINOSHITA S.Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride［J］.J Glaucoma，2003，12（6）：486-490.
［37］ NIIYA A，YOKOI N，MATSUMOTO Y，KOMURO A，ISHIBASHI T，TOMII S，et al.Effect of beta-blocker eyedrops on corneal epithelial barrier function［J］.Ophthalmologica，2000，214（5）：332-336.
［38］ SARKAR J，CHAUDHARY S，NAMAVARI A,OZTURK O,CHANG JH,YCU L，et al.Corneal neurotoxicity due to topical benzalkonium chloride［J］.Invest Ophthalmol Vis Sci，2012，53（4）：1792-1802.
［39］ SATO A，YAMAMOTO M，IMAMURA K，OZTURK O，CHANG JH，YCO L，et al.Pathophysiology of aganglionic colon and anorectum：an experimental stydy on aganglionosis produced by a new method in the rat［J］.J Pediatr Surg，1978，13（4）：399-435.
［40］ FOX DA，EPSTEIN ML，BASS P.Surfactants selectively ablate enteric neurons of the rat jujunum［J］.J Pharmacol Exp Ther，1983，227（2）：538-544.
［41］ HANANI M，LEDDER O，YUTKIN V，ABU-DALU R，HUANG TY，HRTIG W，et al.Regeneration of myenteric plexus in the mouse colon after experimental denervation with benzalkonium chloride［J］.J Comp Neurol，2003，462（3）：315-327.
［42］ PARR EJ，SHARKEY KA.Multiple mechanisms contribute to myenteric plexus ablation induced by benzalkonium chloride in the guinea-pig ileum［J］.Cell Tissue Res，1997，289（2）：253-264.
［43］ MANNI G，CENTOFANTI M，ODDONE F，PARRAVANO M，BUCCI MG.Interleukin-1beta tear concentration in glaucomatous and ocular hypertesive patients treated with preservative-free nonselective beta-blockers［J］.Am J Ophthalmol，2005，139（1）：72-77.
［44］ BOGER WP，PULIAFITO CA，STEINER RF，PAVAN-LANGSTON D.Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma［J］.Ophthalmology，1978，85（3）：259-267.
［45］ BONOMI L，ZAVARISE G，NOYA E，MICHIELETTO S.Effects of timolol maleate on tear flow in human eyes［J］.Graefes Arch Clin Exp Ophthalmol，1980，213（1）：19-22.
［46］ STREMPEL I.The influence of topical beta-blockers on the breakup time［J］.Ophthalmologica，1984，189（3）：110-115.
［47］ CIANCAGLINI M，CARPINETO P，AGNIFILI L，NUBILE M，FASANELLA V，LANZINI M，et al.An in vivo confocal microscopy and impression cytology analysis of perserved and unpreserved levobunolol-induced conjunctival changes［J］.Eur J Ophthalmol，2008，18（3）：400-407.
［48］ NOECKER RJ，HERRYGERS LA，ANWARUDDIN R.Corneal and conjunctival changes caused by commonly used glaucoma medications［J］.Cornea，2004，23（5）：490-496.
［49］ PISELLA PJ，DEBBASCH C，HAMARD P，CREUZOT-GARCHER C，RAT P，BRIGNOLE F，et al.Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol：an ex vivo and in vivo study［J］.Invest Ophthalmol Vis Sci，2004，45（5）：1360-1368.
［50］ STEWART WC，STEWART JA，JENKINS JN，JACKON AL.Corneal punctate staining with latanoprost，bimatoprost，and travoprost in healthy subjects［J］.J Glaucoma，2003，12（6）：475-479.
［51］ STEWART WC，KOLKER AE，STEWART JA，LEECH J,JACKSON AL.Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost，bimatoprost，and travoprost［J］.Am J Ophthalmol，2003，135（3）：314-320.
［52］ HONG S，LEE CS，SEO KY，SEONG GJ，HONG YJ.Effects of topical antiglaucom application on conjunctival impression cytology specimens［J］.Am J Ophthalmol，2006，142（1）：185-186.
［53］ WEISSMAN SS，ASBELL PA.Effects of topical timolol（0.5%） and betaxolol（0.5%） on corneal sensitivity［J］.Br J Ophthalmol，1990，74（7）：408-412.
［54］ KIM JH，KIM EJ，KIM YH，KIM YI，LEE SH，JUNG JC，et al.In vivo effects of preservative-free and preserved prostaglandin analogs：mouse ocular surface study［J］.Korean J Ophthalmol，2015，29（4）：270-279.
［55］ PENNA EP，TABBARA KF.Oxybuprocaine keratopathy：a pre-ventable disease［J］.Br J Ophthalmol，1986，70（3）：202-204.
［56］ KINTNER JC，GROSSNIKLAUS HE，LASS JH，JACOBS G.Infectious crystalline keratopathy associated with topical anesthetic abuse［J］.Cornea，1990，9（1）：77-80.
［57］ HOU YC，WANG IJ，HU FR.Ring keratitis associated with topical abuse of a dilute anesthetic after refractive surgery［J］.J Formos Med Assoc，2009，108（12）：967-972.
［58］ CALONGE M，DIEBOLD Y，SEZ V，ENRQUEZ DE,SAL-AMANCA A，GARCA-VZQUEZ C，et al.Impression cytology of the ocular surface：a review［J］.Exp Eye Res，2004，78（3）：457-472.
［59］ DROY-LEFAIX MT，BUENO L，CARON P，BELOT E，ROCHE O.Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats：a protective effect of a myosin light chain kinase inhibitor［J］.Invest Ophthalmol Vis Sci，2013，54（4）：2705-2710.
［60］ AVUNDUK AM，BEUERMAN RW，VARNELL ED，KAUFMAN HE.Confocal microscopy of Aspergillus fumigatus keratitis［J］.Br J Ophthalmol，2003，87（4）：409-410.
［61］ PARMAR DN，AWWAD ST，PETROLL WM，BOWMAN RW，MCCULLEY JP，CAVANAGH HD.Tandem scanning confocal corneal microscopy in the diagnosis of suspected acanthamoeba keratitis［J］.Ophthalmology，2006，113（4）：538-547.
［62］ ANSARI H，WEINBERG L，SPENCER N.Toxic epitheliopathy from a single application of preservative free oxybuprocaine （0.4%） in a patient with Sjogren’s syndrome［J］.BMJ Case Rep，2013，2013：bcr2013010487.
［63］ PISELLA PJ，POULIQUEN P，BAUDOUIN C.Prevalence of ocular symptoms and signs with preserved and preservative free glaucom medication［J］.Br J Ophthalmol，2002，86（4）：418-423.
［64］ YEE RW.The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy：a review［J］.Curr Opin Ophthalmol，2007，18（2）：134-139.
［65］ HOLLAND S，MORCK D，SCHULTZ C.Treatment of corneal defects with delayed re-epithelization with a medical device/drug delivery system for epidermal growth factor［J］.Clin Experiment Ophthalmol，2012，40（7）：662-668.
［66］ LEE SH，TSENG SC.Amniotic membrane transplantation for persistent epithelial defects with ulceration［J］.Am J Ophthalmol，1997，123（3）：303-312.
［67］ 明春平，史伟云，李曼，张菊，庄宪丽.部分永久性睑缘缝合术治疗持续性角膜上皮缺损27例［J］.眼科新进展，2008，28（6）：449-451.
MING CP,SHI WY,LI M,ZHANG J,ZHUANG XL.Partial permanent tarsorrhaphy in treatment of 27 cases with persistent corneal epithelial defect［J］.Rec Adv Ophthalmol,2008,28(6):449-451.
［68］ DI PASCUALE MA，ESPANA EM，KAWAKITA T，TSENG SC.Clinical characteristics of conjunctivochalasis with or without aqueous tear deficiency［J］.Br J Ophthalmol，2004，88（3）：388-392.
［69］ KOCABEYOGLU S，MOCAN MC，IRKEC M.The influence of glaucoma medications on ocular surface disease in primary open-angle glaucoma patients with and without conjunctivochalasis［J］.Acta Ophthalmol，2014，92（7）：e592-593.
［70］ TOKUDA N，KITAOKA Y，MATSUZAWA A，MIYAMOTO J，SAKAE S，MUNEMASA Y，et al.The effect of rebamipide on ocular surface disorders induced by latanoprost and timolol in glaucoma patients［J］.J Ophthalmol，2015，2015：1-5.
相似文献/References:
[1]魏瑞华 郝永娜 边领斋 李雪 粘红 赵少贞.Sjogren综合征相关性干眼发病机制的研究进展[J].眼科新进展,2013,33(3):000.
[2]樊维,谢琳.糖尿病视网膜病变易感基因的研究进展[J].眼科新进展,2016,36(2):190.[doi:10.13389/j.cnki.rao.2016.0052]
FAN Wei,XIE Lin.Recent advances in susceptibility genes of diabetic retinopathy[J].Recent Advances in Ophthalmology,2016,36(2):190.[doi:10.13389/j.cnki.rao.2016.0052]
[3]尹婕,徐文芹,王雨生.小胶质细胞的特征及其在视网膜疾病中的作用[J].眼科新进展,2016,36(3):283.[doi:10.13389/j.cnki.rao.2016.0077]
YIN Jie,XU Wen-Qin,WANG Yu-Sheng.Properties of microglia and its functions in retinal diseases[J].Recent Advances in Ophthalmology,2016,36(2):283.[doi:10.13389/j.cnki.rao.2016.0077]
[4]张凤俊,易敬林,李晶明,等.糖尿病视网膜病变发病机制研究进展[J].眼科新进展,2016,36(6):584.[doi:10.13389/j.cnki.rao.2016.0155]
ZHANG Feng-Jun,YI Jing-Lin,LI Jing-Ming,et al.Recent advances in pathological mechanisms of diabetic retinopathy[J].Recent Advances in Ophthalmology,2016,36(2):584.[doi:10.13389/j.cnki.rao.2016.0155]
[5]尹婕,李郁,王雨生.Basigin的分子作用机制及其在眼部的生物学功能[J].眼科新进展,2016,36(10):979.[doi:10.13389/j.cnki.rao.2016.0263]
YIN Jie,LI Yu,WANG Yu-Sheng.Molecule mechanism of Basigin and its special biological function in eye[J].Recent Advances in Ophthalmology,2016,36(2):979.[doi:10.13389/j.cnki.rao.2016.0263]
[6]孙飒,张俊杰.抑郁症与干眼关系研究进展[J].眼科新进展,2016,36(11):1090.[doi:10.13389/j.cnki.rao.2016.0291]
SUN Sa,ZHANG Jun-Ji.Research advances in relationship between depression and dry eye[J].Recent Advances in Ophthalmology,2016,36(2):1090.[doi:10.13389/j.cnki.rao.2016.0291]
[7]刘祁,李东旭,王阜蕾,等.大鼠半乳糖性白内障晶状体上皮细胞的病理变化[J].眼科新进展,2016,36(12):1101.[doi:10.13389/j.cnki.rao.2016.0294]
LIU Qi,LI Dong-Xu,WANG Fu-Lei,et al.Pathological changes of lens epithelial cells in galactosemic cataract model of rats[J].Recent Advances in Ophthalmology,2016,36(2):1101.[doi:10.13389/j.cnki.rao.2016.0294]
[8]郭芳,魏瑞华,吴绵绵,等.近视动物模型及发病机制的研究进展[J].眼科新进展,2018,38(5):490.[doi:10.13389/j.cnki.rao.2018.0115]
GUO Fang,WEI Rui-Hua,WU Mian-Mian,et al.Research advances in the animal models and pathogenic mechanisms of myopia[J].Recent Advances in Ophthalmology,2018,38(2):490.[doi:10.13389/j.cnki.rao.2018.0115]
[9]伍雪,张锐.葡萄膜黑色素瘤相关炎症浸润细胞及免疫治疗[J].眼科新进展,2019,39(3):282.[doi:10.13389/j.cnki.rao.2019.0064]
WU Xue,ZHANG Rui.Inflammatory infiltrating cells related to uveal melanoma and its immunotherapy[J].Recent Advances in Ophthalmology,2019,39(2):282.[doi:10.13389/j.cnki.rao.2019.0064]
[10]马超,刘薇,李凯军,等.甲状腺相关眼病免疫相关发病机制的研究现状与进展[J].眼科新进展,2019,39(8):790.[doi:10.13389/j.cnki.rao.2019.0180]
MA Chao,LIU Wei,LI Kai-Jun,et al.Current status and progress of immune related pathogenesis in thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2019,39(2):790.[doi:10.13389/j.cnki.rao.2019.0180]